Yüklüyor......
Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects
Treatment options have significantly expanded in recent years for men with metastatic castration-resistant prostate cancer (mCRPC), with the routine use of immunotherapy (sipuleucel-T) and novel hormonal agents such as enzalutamide and abiraterone acetate prior to taxane-based chemotherapy or radium...
Kaydedildi:
| Yayımlandı: | Ther Adv Urol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4707420/ https://ncbi.nlm.nih.gov/pubmed/26834836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215603558 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|